Blood conservation in the critically ill

American Journal of Health-System Pharmacy

Volumn 64, Issue 16 SUPPL., 2007, Pages

  Thomas, Jennifer ^a   Martinez, Anthony ^b  

^a ST AGNES HOSPITAL   (United States)

^b St Agnes Hospital   (United Kingdom)

Author keywords

Anemia; Ascorbic acid; Blood; Costs; Critical illness; Cyanocobalamin; Dosage; Epoetin alfa; Errors, medication; Folic acid; Hematopoietic agents; Hospitals; Iron preparations; Iron sucrose; Mortality; Vitamins

Indexed keywords

ANTIANEMIC AGENT; ASCORBIC ACID; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON; IRON SACCHARATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; BLOOD CONSERVATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ERROR; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; IRON BINDING CAPACITY; LABORATORY TEST; LENGTH OF STAY; MORTALITY; PARAMETER; PHARMACODYNAMICS; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETICULOCYTE COUNT; TRANSFERRIN SATURATION; TREATMENT RESPONSE;

EID: 34547904668     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070245     Document Type: Conference Paper

References (33)

1. Vincent JL, Baron JF, Reinhart K et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002; 288:1499-1507.
2. Corwin HL, Gettinger A, Pearl RG et al. The CRIT Study: Anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med. 2004; 32:39-52.
3. Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999; 340:409-17.
4. Vamvakas EC, Blajchman MJ. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001; 97:1180-95.
5. Nouwairi NS. The risks of blood transfusions and the shortage of supply leads to the quest for blood substitutes. AANA J. 2004; 72:359-64.
6. Blood Shortage. October 25, 2000. www.pbs.org/newshour/bb/health/july- dec00/blood_shortage.html (accessed 2007 Feb 16).
7. American Red Cross makes emergency appeal. Regional blood shortage potentially threatens elective surgeries. redcrossgulfcoast.org/news/06/060706. htm (accessed 2007 Feb 16).
8. Greater Chesapeake and Potomac (GC & P) Blood Services Region of the American Red Cross. Critical blood shortage continues throughout region. August 28, 2006. www.my-redcross.org/documents/08282006PressRelease.pdf (accessed 2007 Feb 16).
9. van Iperen CE, Gaillard CA, Kraaijenhagen RJ et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med. 2000; 28:2773-8.
10. Corwin HL, Gettinger A, Rodriguez RM et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999; 27:2346-50.
11. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002; 288:2827-35.
12. Thomas J, Parce P, Spence R et al. Evaluation of epoetin alfa pharmacodynamics in critically ill patients. Poster presented at the annual meeting of the Society for the Advancement of Blood Management; September 16-18, 2005, Phoenix AZ.
13. Martinez A, Fomengia C, Thomas J et al. Re-evaluation of ICU blood management strategies and metrics. Poster presented at the annual meeting of the Society for the Advancement of Blood Management; September 15-17, 2006, Jersey City NJ.
14. Package insert. Procrit (epoetin alfa). Raritan, NJ: Ortho Biotech Products, January 2005.
15. Cheung WK, Goon BL, Guilfoyle MC et al. Pharmacokinetics and pharmaocodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998; 64:412-23.
16. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001; 37(suppl 1):S182-S288.
17. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006; 47(suppl 3):S1-S146.
18. CARI Guidelines - Caring for Australians with Renal Impairment 1999, 2006. The CARI guidelines. Haematological targets. Iron. Nephrology. 2006; 11(Suppl 1): S217-29.
19. Goodnough TL, Skikne B, Brugnara C. Erythropoiesis, iron, and erythropoiesis. Blood. 2000; 96:823-33.
20. Moe OW, Vasquez M, Kelar M. Iron metabolism in end stage renal failure: rationale for re-evaluation of parenteral iron therapy. Curr Opin Nephrol Hypertens. 2003; 12:145-151.
21. Taylor RW, Manganaro L, O'Brien J et al. Impact of allogeneic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med. 2002; 30:2249-54.
22. Mulder HC, de Wilde RB, van den Berg PC et al. Storage time of transfused blood in the intensive care unit. Crit Care Med. 2004; 32(Suppl):A163. (Abstract)
23. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352:1011-23.
24. Rodriguez RM, Corwin HL, Gettinger A et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care. 2001; 16:36-41.
25. Vincent JL, Spapen HD, Creteur J et al. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2006; 34:1661-7.
26. Food and Drug Administration Center for Drug Administration and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) FDA Alert [3/09/2007]. www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm (accessed 2007 Apr 17).
27. Nucci ML, Abuchowski A. The search for blood substitutes. Sci Am. 1998; 278:72-9.
28. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA 10: Study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. http://frejacms.au.dk/dahanca/get_media_file.pdf (accessed 2007 Apr 17).
29. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy. www.clinicalstudyresults.org/ documents/company-study_21557_0.pdf (accessed 2007 Apr 17).
30. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non?small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007; 25:1027-32.
31. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemia patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23:5960-72.
32. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
33. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-84.